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ABSTRACT
Tuberculosis (TB) during pregnancy and in the perinatal period was once considered to be an
infrequent event in the United States. After a decade of steady decline, however, the disease has
begun a resurgence. According to the CDC, a 20% increase in the number of reported cases
occurred between 1985 and 1992. The factors associated with this increase are the emergence of
human immunodeficiency virus (HIV) infection, the development of drug-resistant organisms,
substance abuse, homelessness, and immigration. Environmental factors promoting transmission
can be found in overcrowded areas such as correctional facilities, nursing homes, hospitals, and
migrant-worker camps. For a large number of medically underserved women, the obstetrician is
the only interface with medical care, as most of these patients do not have primary-care providers.
It is important, therefore, that health-care providers recognize the clinical symptoms of TB and
follow the recognized guidelines for antenatal screening for TB because the omission of these steps
can lead to potentially disastrous sequelae in the fetus and neonate. (C) 1996 Wiley-Liss, Inc.
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uberculosis (TB) is one of the most common
chronic infectious diseases worldwide. Annu-
ally, approximately 7 million new cases are diag-
nosed, with 2 million deaths directly attributable
to the disease. In the United States, from the begin-
ning of the century to 1985, a decline from 100,000
to 20,000 new cases was noted. 1’2 From 1985 to 1992,
however, a marked increase in new cases occurred.
Several factors account for this rise including the
increasing rate of immigrants from endemic areas
of the world such as Asia, Africa, and Latin America;
the burgeoning rates of homelessness and poverty;
the emergence of resistant organisms; and, most
importantly, the emergence ofacquired immunode-
ficiency syndrome (AIDS).
At all times, the poor have been a major group
affected by TB. The disease tends to occur in clus-
ters or nests based on racial or ethnic minority
groups with low socioeconomic status. An overview
of deaths from TB in 1985 revealed the mortality
rate for nonwhites to be 3.7 times the rate for whites.
The age distribution also demonstrates a marked
difference in the rates ofdisease between minorities
and whites. Approximately 40% of cases among
nonwhites occur prior to the age of 35 years, while,
in whites, the majority of cases occur around the
age of 65 years.
Since the prevalence ofTB affects a large num-
ber ofyoung adults, the same age group constitutes
the largest number of patients infected with human
immunodeficiency virus (HIV), specifically, the
15-49-year-old age group. The interaction between
these 2 diseases poses a 2-fold problem: the unusual
extrapulmonary manifestations that are more likely
to occur in this population present a diagnostic chal-
lenge and, with the high prevalence of drug resis-
tance, important considerations must be addressed
when selecting therapy.
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PATHOGENESIS
The infectious agent ofTB, Mycobacterium tubercu/o-
s/s, is the main human pathogen of the genus Myco-
bacterium, followed byM. leprae, the causative organ-
ism of leprosy. Other members of the genus known
to cause human disease are M. bovis and the atypical
mycobacterium. The former organism was once re-
sponsible for disease in humans prior to the pasteur-
ization of milk, while the latter is responsible for
the majority of cases of TB in immunosuppressed
individuals.
M. tuberculosis is spread by airborne transmission
in >90% of the reported cases. Droplet nuclei are
produced when an individual with active disease
coughs, sneezes, speaks, or sings. The manipulation
of lesions and processing of tissues or secretions
infected with the organism may also produce drop-
let nuclei. After inhalation, the nuclei pass down
the bronchial tree and implant themselves in a re-
spiratory bronchiole or alveolus beyond the muco-
ciliary clearance system. The bacilli subsequently
multiply, usually without any initial resistance from
the host. Occasionally, the patient experiences fe-
ver, cough, and pleuritic chest pain. The organisms
are subsequently engulfed by macrophages, where
they remain viable and multiply. After the initiation
of an infection, the organisms leave the primary
focus in the lung and arrive at regional lymph nodes.
From there, they may disseminate throughout the
body by lymphohematogenous spread. The organs
most commonly seeded during this phase are the
lung apices, spleen, liver, meninges, bones, and
joints. The genitalia and placenta may also be in-
volved.
After 1-2 months, the host develops cell-medi-
ated immunity and hypersensitivity to the tubercle
bacillus which is reflected by the development of
a positive tuberculin skin-test result. As immunity
develops, the primary infection in the lungs and
other organs begins to heal through a combination
of resolution, fibrosis, and calcification. Although
healing occurs, viable bacilli may persist for many
years. If the host later becomes immunosuppressed,
e.g., HIV infected, these viable bacilli may again
become active, leading to the reactivation ofpulmo-
nary TB.
Certain disease states, such as diabetes, and
medications, such as corticosteroids and other im-
munosuppressive drugs, reduce the ability of the
GAITHER AND APUZZIO
host to respond to the organism. An HIV infection,
because of its profound immunosuppression, pre-
disposes an individual to more severe forms of TB.
In such a patient, dissemination of the bacilli, with
unusual clinical manifestations of extrapulmonary
disease, is common.
It is important that the definition of the 2 phases
of infection be clarified: Tuberculosis infection is the
preclinical stage ofM. tuberculosis; Tuberculosis disease
occurs when there are clinical manifestations of pul-
monary or extrapulmonary involvement and a posi-
tive chest X-ray.
CLINICAL FINDINGS OF ACTIVE DISEASE
Characteristically, in pulmonary TB, there is an on-
set of cough, which typically progresses over weeks
to months. The cough subsequently becomes more
frequent, with the production of mucoid or muco-
purulent sputum. Hemoptysis may also occur. A
recurring, dull, aching pain or chest tightness is
common. Dyspnea is uncommon unless massive
lung parenchymal involvement occurs. Some pa-
tients present with the acute onset of productive
cough, fever, chills, myalgias, and sweating, similar
to the signs and symptoms of influenza, acute bron-
chitis, or pneumonia. The physical findings may
include rales or signs of lung consolidation, which
are generally unilateral.
SCREENING AND DIAGNOSIS
It is important that all pregnant women at the first
prenatal visit be questioned about current symp-
toms compatible with TB; a previously positive tu-
berculin test; bacille Calmette-Gu6rin (BCG) vacci-
nation; previous treatment; membership in a high-
risk group; or employment in a hospital, nursing
home, or prison. Although any of these situations
is sufficient reason for a tuberculin skin test, most
physicians feel that all pregnant women should be
skin tested.
The tuberculin skin test is based on the fact that
an infection withM. tuberculosis produces sensitivity
to certain antigenic components of the organism.
The purified protein derivative (PPD) test is the
best means ofdetecting an infection withM. tubercu-
losis. Furthermore, the patterns of reaction are im-
portant in establishing follow-up and preventive
therapy with antituberculous agents.
One-tenth of a milliliter of PPD is injected sub-
cutaneously into either the volar or the dorsal sur-
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 93TUBERCULOSIS IN PREGNANCY GAITHER AND APUZZIO
face of the forearm. A wheal of 6-10 mm should
be produced if the injection is given correctly. The
test should be read between 48 and 72 h later by
an experienced health-care provider. The presence
or absence of induration is the basis of the reading.
For a woman who is at high risk for HIV or who is
HIV positive, a delayed-type hypersensitivity an-
ergy test should be employed. Typically, the anti-
gens used are those for mumps, candida, or Tricho-
phyton. The diameter of induration should be
measured transversely to the long axis of the fore-
arm and recorded in millimeters. According to the
American Thoracic Society, a reaction of >5 mm
is classified as positive for patients in the following
groups: patients with HIV or patients with risk fac-
tors and an unknown status; patients with close,
recent contact with infectious TB cases; and pa-
tients with chest X-rays consistent with old (healed)
TB. A reaction of > 10 mm is classified as positive
in persons not meeting the above criteria who have
other risk factors for TB, including the following
groups: foreign-born persons, particularly from Asia,
Africa, and Latin America; patients with preexisting
medical conditions such as diabetes mellitus or ma-
lignancies that place them at increased risk; medi-
cally underserved, low-income populations; and
health-care workers.
There exists no definitive method ofdistinguish-
ing a tuberculin reaction caused by a natural myco-
bacterial infection from a reaction caused by a BCG
vaccination. Generally, a reaction size of> 10 mm is
considered positive for a patient who has previously
received BCG, particularly if the immunization oc-
curred more than a decade previously. Among the
multiple reasons for not assuming that a large reac-
tion is secondary to BCG are that tuberculin sensi-
tivity tends to wane after vaccination and the mean
reaction size among persons vaccinated is often < 10
ram. As many BCG-vaccinated individuals come
from areas of the world where TB is endemic, an
individual with a significant reaction to tuberculin
skin testing should be further evaluated for the
presence of disease and managed accordingly.
SPECIMEN COLLECTION
Because the identification of mycobacteria is im-
portant in diagnosing TB, the proper collection and
handling of specimens are imperative. A culture of
the organism is mandatory for a definitive diagnosis
of the disease. M. tuberculosis is an obligate aerobe
that is slow growing in classic culture media, often
taking weeks for identification. Recently, however,
a rapid radiometric method, the BACTEC method
(BACTEC, Johnston Laboratories, Towson, MD)
has become available for the detection and differen-
tiation of mycobacteria and drug-susceptibility test-
ing.6The BACTEC technique permits a rapid diag-
nosis in days compared with weeks or even months
with the classic culture media.
Although radiometric technology cannot com-
pletely replace the standard mycobacteriologic cul-
ture methods and may underestimate drug resis-
tance, it is a valuable new tool. Other methods for
microbiologic identification include genetic probes,
enzyme-linked immunosorbent assays (ELISA),
mycobacteriophage typing, and high-performance
liquid chromatography (HPLC) to detect species-
specific mycolic acids.
Since tuberculous disease can occur in almost
any site in the body, a variety of materials may be
substituted for collection. In addition to the most
common specimens such as sputum and gastric aspi-
rate, urine, cerebrospinal fluid, pus, and bronchial
washings can be submitted. A placental examina-
tion can lead to detection in the mother.
TB IN PREGNANCY
Throughout history, medical opinion concerning
the effect of pregnancy on the course of TB has
varied. Prior to the 18th century, pregnancy was
viewed as having a beneficial effect. In contrast,
the opinion held nearly a century later was that
pregnancy imposed a detrimental effect on the
course of TB justifying the recommendation for a
therapeutic abortion. Pregnancy does not appear to
be a risk factor for the development of TB, nor
does it accelerate the clinical course ofthe diseasem
even in HIV-infected women. 8’9 TB is seldom an
indication for an abortion unless massive dissemina-
tion or severely compromised cardiopulmonary
function occurs. Problems in managingTB in preg-
nant patients are usually not due to any potential
maternal respiratory impairment, but to the possible
teratogenic effects of antituberculous medication.
During pregnancy, a positive tuberculin test is
evaluated by a chest X-ray with abdominal shielding
of the gravid uterus. Radiation exposure to the fetus
with proper shielding has been estimated to be <0.3
millirad. 1’1zA woman with a suspicious chest X-ray
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for active disease should undergo 3 early morning
sputum samples for culture and smear.
A pregnant woman with a positive PPD, without
evidence of active disease on her chest X-ray,
should undergo isoniazid prophylaxis. The prophy-
lactic regimen consists of isoniazid for 6-12 months
starting in the postpartum period.
A woman with HIV infection or risk factors who
refuses testing should also be treated prophylac-
tically for a positive PPD. For such a woman, 4
months of isoniazid and rifampin or 12 months of
isoniazid is recommended, providing that drug-re-
sistant organisms are unlikely.
13 In a pregnant pa-
tient, however, who has a recent conversion (within
the last 2 years) or close contact with someone with
active disease, prophylaxis is initiated after the
first trimester.
In contrast to this recommendation, a patient
with active disease should begin chemoprophylaxis
immediately regardless of the gestational age. Un-
treated TB poses a greater hazard to the pregnant
woman and her fetus than the treatment of the
disease does. Once sputum cultures have been ob-
tained to confirm the diagnosis with indicated sus-
ceptibilities, the pregnant woman with TB should
receive multidrug chemotherapy for 9 months. The
treatment of the disease consists of isoniazid, rifam-
pin, and ethambutol. Vitamin B6 is indicated for
all pregnant women taking isoniazid. Although pyr-
azinamide has been used abroad for the treatment
of disease, it is not used during pregnancy in the
United States because of concerns of potential tera-
togenicity.
14
ANTITUBERCULOUS MEDICATIONS
Isoniazid, ethambutol, and rifampin have all been
evaluated for potential fetal effects during preg-
nancy. To date, none has been found to be terato-
genie. All 3 drugs are bactericidal. Furthermore,
all 3 cross the placenta as well as appear in the
breast milk.
Isoniazid is the most widely used chemothera-
peutic drug for TB. It is easily administered and
inexpensive. It can be given orally or by intramuscu-
lar injection. The recommended dose is 300 rag/
day. Although it is excreted in breast milk, its use
during the postpartum period does not contraindi-
cate breast-feeding so long as there is adequate
pediatric follow-up. The potential side effects of
isoniazid include hepatitis and peripheral neuropa-
thy. It is useful to obtain baseline serum transami-
nase levels at the beginning of therapy and monitor
the patient clinically for adverse reactions during
the course ofpregnancy. As isoniazid interferes with
the metabolism of pyridoxine, causing peripheral
neuritis, 50 mg/day of vitamin B6 is recommended.
The usual dose of ethambutol is 15 mg/kg. Ret-
robulbar neuritis is the most serious side effect,
the symptoms including red-green color blindness,
blurred vision, and central scotomata. The ocular
effects are dose related and generally noted in pa-
tients with renal insufficiency.
The recommended dosage of rifampin is 10 mg/
kg, with a usual daily dosage of 600 mg/day. The
most common adverse reaction is gastrointestinal
upset.
CONGENITAL TB
Congenital TB is extremely rare, with <200 cases
reported in the literature.5 Neonatal TB can either
be truly congenital (acquired in utero) or truly neo-
natal (acquired in early life from an infected mother
or caretaker). Congenital TB may be acquired
through 3 routes: 1) from the infected placenta
through hematogenous dissemination from the um-
bilical vein, 2) by inhalation of infected amniotic
fluid, or 3) by ingestion of infected amniotic fluid.
In hematogenously acquired congenital TB, the
organisms reach the fetus through the umbilical
vein. Generally, a primary focus develops in the
fetal liver, with associated involvement of the peri-
portal lymph nodes. However, the bacilli can also
pass through the liver into the main circulation,
leading to a primary focus in the lung where it
remains dormant until birth.
Inhalation or ingestion of infected amniotic fluid
by the fetus results from caseous placental lesions
rupturing into the amniotic cavity. In this instance,
multiple foci are present in the lung, gut, and mid-
dle ear.
Postnatal TB can be acquired in 4 different ways:
1) by inhalation of infected droplets, 2) by ingestion
of infected droplets, 3) by ingestion of infected
milk, or 4) by contamination of traumatized skin
or mucous membranes. Because newborns infected
with TB are at extremely high risk of developing
severe forms of the disease, the investigation of a
person with TB whose household contains a preg-
nant woman or newborn infant should be consid-
ered a public-health emergency.
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CONCLUSIONS
With the increase in reported cases of TB along
with the spread of drug-resistant strains, heightened
vigilance concerning recognition, prevention, and
treatment has begun. The obstetric patient with
active disease not only exposes healthy individuals
to the organism, but her fetus as well. With appro-
priate history-taking and screening, TB can be diag-
nosed and treated successfully. A woman’s pre- and
post-delivery care represents the best opportunity
for such an outcome.
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